Mumbai, June 5 -- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB Inc. According to IQVIA sales data for the 12-month period ended April 2026, the Vimpat Injection market recorded annual sales of approximately $15.2 million in the United States.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitme...